

## UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
10/045,400	11/29/2001	Chulso Moon P-CAN 1004		4431	
7590 09/29/2004			EXAM	EXAMINER	
LISA M HEMMENDINGER BANNER & WITCOFF LTD			YU, MISOOK		
1001 G STREET NW			ART UNIT	PAPER NUMBER	
ELEVENTH FL			1642		
WASHINGTON, DC 20001-4597			DATE MAILED: 09/29/2004		

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
	10/045,400	MOON ET AL.			
Office Action Summary	Examiner	Art Unit			
	MISOOK YU, Ph.D.	1642			
The MAILING DATE of this communication app					
Period for Reply  A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be time within the statutory minimum of thirty (30) days will apply and will expire SIX (6) MONTHS from cause the application to become ABANDONEI	ely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on 29 No					
<u> </u>	,				
Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims					
4) ⊠ Claim(s) 1 and 27-42 is/are pending in the appleada of the above claim(s) is/are withdray 5) □ Claim(s) is/are allowed.  6) □ Claim(s) is/are rejected.  7) □ Claim(s) is/are objected to.  8) ⊠ Claim(s) 1, 27-42 are subject to restriction and/	vn from consideration.				
Application Papers					
9) The specification is objected to by the Examiner 10) The drawing(s) filed on is/are: a) access applicant may not request that any objection to the conference of th	epted or b) objected to by the Eddrawing(s) be held in abeyance. See ion is required if the drawing(s) is obj	e 37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).			
Priority under 35 U.S.C. § 119					
<ul> <li>12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents</li> <li>2. Certified copies of the priority documents</li> <li>3. Copies of the certified copies of the prior application from the International Bureau</li> <li>* See the attached detailed Office action for a list of the certified copies</li> </ul>	s have been received. s have been received in Application ity documents have been receive I (PCT Rule 17.2(a)).	on No ed in this National Stage			
Attachment(s)					
Notice of References Cited (PTO-892)     Notice of Draftsperson's Patent Drawing Review (PTO-948)     Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)     Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal Pa	(PTO-413) Ite atent Application (PTO-152)			

Application/Control Number: 10/045,400

Art Unit: 1642

## **DETAILED ACTION**

## Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- Claim 1, drawn to method of diagnosing lung cancer by detecting a lower expression of DAP-kinase, classified in class 435, subclass 6.
- II. Claims 27-37, drawn to method of diagnosing NSCLC by detecting a higher expression of HOX9 gene, classified in class 435, subclass 6.
- III. Claims 38, 39, 41, and 42, drawn to method of inhibiting tumorigenesis, progression of NSCLC tumor, or treating tumor by inhibiting expression of HOXA9, unclassifiable due to an unknown nature of the active ingredient used in the active step of the claims.
- VI. Claim 40, drawn to method of screening a compound that could be used in inhibiting tumorigenesis, progression, or treating NSCLC tumor, by inhibiting expression of HOXA9, unclassifiable due to the unknown nature of the active ingredient.

The inventions are distinct, each from the other because of the following reasons:

Inventions I-IV are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are drawn to different methods with different reagents for different purposes. Group I involves searching of whether lower expression of DAP-kinase is indication of lung cancer, while group II involves a different

Application/Control Number: 10/045,400

Art Unit: 1642

gene expression i.e. a higher expression of HOXA9; the search is not coextensive because two are separate gene and one appears to be a tumor suppressor and the other enhancing tumor development. Groups VI is drawn to method to screen a compound that could be used in group III method. These two methods cannot be used together because group VI method has to be conducted first before proceeding to group III method. Search of group IV and treatment method of group IV is not coextensive because group IV involves searching of treatment art, while group III does not.

The search required for each group is not required for the other groups because each group requires a different non-patent literature search due to each group comprising different products and/or method steps, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MISOOK YU, Ph.D. whose telephone number is 571-

Art Unit: 1642

272-0839. The examiner can normally be reached on 8 A.M. to 5:30 P.M., every other Friday off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jeffrey C Siew can be reached on 571-272-0787. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

MISOOK YU, Ph.D. Examiner Art Unit 1642

> LAHRY R. HELMS, PH.D. PRIMARY EXAMINER